Ritter Pharmaceuticals has announced the dosing of the first patient in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance.
from NutraIngredients RSS http://ift.tt/1Skc0o5
via IFTTT
information on Dietary Supplements
Ritter Pharmaceuticals has announced the dosing of the first patient in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance.